Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,617 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mutations associated with the therapeutic efficacy of adefovir dipivoxil added to lamivudine in patients resistant to lamivudine with type B chronic hepatitis.
Ohkawa K, Takehara T, Kato M, Kanada A, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, Yamaguchi S, Miyagi T, Ishida H, Tatsumi T, Hayashi N. Ohkawa K, et al. Among authors: hayashi n. J Med Virol. 2009 May;81(5):798-806. doi: 10.1002/jmv.21348. J Med Virol. 2009. PMID: 19319954 Clinical Trial.
Involvement of dendritic cell frequency and function in virological relapse in pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C patients.
Itose I, Kanto T, Inoue M, Miyazaki M, Miyatake H, Sakakibara M, Yakushijin T, Oze T, Hiramatsu N, Takehara T, Kasahara A, Katayama K, Kato M, Hayashi N. Itose I, et al. Among authors: hayashi n. J Med Virol. 2007 May;79(5):511-21. doi: 10.1002/jmv.20809. J Med Virol. 2007. PMID: 17385691 Clinical Trial.
Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B.
Kurashige N, Hiramatsu N, Ohkawa K, Yakushijin T, Kiso S, Kanto T, Takehara T, Kasahara A, Doi Y, Yamada A, Oshita M, Mita E, Hagiwara H, Nagase T, Yoshihara H, Hayashi E, Imai Y, Kato M, Kashihara T, Hayashi N. Kurashige N, et al. Among authors: hayashi e, hayashi n. J Gastroenterol. 2009;44(6):601-7. doi: 10.1007/s00535-009-0038-6. Epub 2009 Apr 22. J Gastroenterol. 2009. PMID: 19387534
Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance.
Kurashige N, Ohkawa K, Hiramatsu N, Yakushijin T, Mochizuki K, Oze T, Kiso S, Kanto T, Takehara T, Kasahara A, Doi Y, Yamada A, Fukuda K, Oshita M, Mita E, Fukui H, Nagase T, Yoshihara H, Imai Y, Kato M, Kashihara T, Hayashi N. Kurashige N, et al. Among authors: hayashi n. J Gastroenterol. 2009;44(8):864-70. doi: 10.1007/s00535-009-0076-0. Epub 2009 May 28. J Gastroenterol. 2009. PMID: 19475333 Clinical Trial.
Fatal exacerbation of type B chronic hepatitis triggered by changes in relaxed circular viral DNA synthesis and virion secretion.
Ohkawa K, Takehara T, Ishida H, Kodama T, Shimizu S, Hikita H, Yamamoto M, Kohga K, Sasakawa A, Uemura A, Sakamori R, Yamaguchi S, Li W, Hosui A, Miyagi T, Tatsumi T, Katayama K, Hayashi N. Ohkawa K, et al. Among authors: hayashi n. Biochem Biophys Res Commun. 2010 Mar 26;394(1):87-93. doi: 10.1016/j.bbrc.2010.02.114. Epub 2010 Feb 20. Biochem Biophys Res Commun. 2010. PMID: 20175994
3,617 results